These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oral miltefosine in the treatment of kala-azar. Mohan A; Seth S Natl Med J India; 2000; 13(4):202-3. PubMed ID: 11002688 [No Abstract] [Full Text] [Related]
6. Visceral leishmaniasis with concomittant post kala-azar dermal leishmaniasis responds to oral sitamaquine: case report. Mbui J; Rashid R; Lodenyo H; Nyakundi P; Kipmutai R; Mutuma G; Kirigi G; Kinoti D; Wasunna M East Afr Med J; 2003 Aug; 80(8):440-2. PubMed ID: 14601788 [TBL] [Abstract][Full Text] [Related]
7. Kala-azar--progress against a neglected disease. Murray HW N Engl J Med; 2002 Nov; 347(22):1793-4. PubMed ID: 12456856 [No Abstract] [Full Text] [Related]
8. [A case of antimony resistant kala-azar cured with amphotericin B]. Chen SB; Yang CM; Zhang CJ Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2007 Jun; 25(3):inside front page. PubMed ID: 18038767 [No Abstract] [Full Text] [Related]
9. Oral miltefosine in post-kala-azar dermal leishmaniasis--experience in three cases. Khandpur S; Chaturvedi P; Kumar U; Khaitan BK; Samantaray JC; Sharma VK Int J Dermatol; 2010 May; 49(5):565-9. PubMed ID: 20534094 [No Abstract] [Full Text] [Related]
10. Orally effective drugs for kala-azar (visceral leishmaniasis): focus on miltefosine and sitamaquine. Sangraula H; Sharma KK; Rijal S; Dwivedi S; Koirala S J Assoc Physicians India; 2003 Jul; 51():686-90. PubMed ID: 14621038 [TBL] [Abstract][Full Text] [Related]
11. Post-kala-azar dermal leishmaniasis caused by Leishmania infantum in an immunocompetent patient. Sánchez-Albisua B; Polimón I; Pérez-Tato B; Marinero S; Fernández-López P Int J Dermatol; 2013 Jul; 52(7):897-9. PubMed ID: 23675968 [No Abstract] [Full Text] [Related]
12. Improved treatment of visceral leishmaniasis (kala-azar) by using combination of ketoconazole, miltefosine with an immunomodulator-Picroliv. Shakya N; Sane SA; Vishwakarma P; Bajpai P; Gupta S Acta Trop; 2011 Aug; 119(2-3):188-93. PubMed ID: 21679679 [TBL] [Abstract][Full Text] [Related]
13. Development of post-kala-azar dermal leishmaniasis in AmBisome treated visceral leishmaniasis: a possible challenge to elimination program in India. Das VN; Pandey K; Singh D; Forwood C; Lal CS; Das P J Postgrad Med; 2013; 59(3):226-8. PubMed ID: 24029204 [TBL] [Abstract][Full Text] [Related]
14. Blindness following visceral leishmaniasis: a neglected post-kala-azar complication. Khalil EA; Musa AM; Younis BM; Elfaki ME; Zijlstra EE; Elhassan AM Trop Doct; 2011 Jul; 41(3):139-40. PubMed ID: 21676981 [TBL] [Abstract][Full Text] [Related]
16. Treatment of leishmaniasis with miltefosine: 2008 status. Berman JJ Expert Opin Drug Metab Toxicol; 2008 Sep; 4(9):1209-16. PubMed ID: 18721114 [TBL] [Abstract][Full Text] [Related]
17. The treatment of kala-azar--new approaches to an old problem. Peters W Indian J Med Res; 1981 Jan; 73 Suppl():1-18. PubMed ID: 6897932 [No Abstract] [Full Text] [Related]
18. Post-kala-azar dermal leishmaniasis (PKDL) developing after treatment of visceral leishmaniasis with amphotericin B and miltefosine. Kumar D; Ramesh V; Verma S; Ramam M; Salotra P Ann Trop Med Parasitol; 2009 Dec; 103(8):727-30. PubMed ID: 20030997 [No Abstract] [Full Text] [Related]
19. Post-kala-azar dermal leishmaniasis with visceral leishmaniasis: a rare presentation. Rijal A; Agrawal S; Agarwalla A; Agrawal A; Rijal S Int J Dermatol; 2005 Jun; 44(6):494-6. PubMed ID: 15941439 [No Abstract] [Full Text] [Related]
20. Comment on: Unresponsiveness to AmBisome in some Sudanese patients with kala-azar. de Górgolas M Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):1054; author reply 1054-5. PubMed ID: 17651771 [No Abstract] [Full Text] [Related] [Next] [New Search]